Potentia Pharmaceuticals said POT-4, a treatment for age-related macular degeneration, was well-tolerated and did not cause adverse events or side effects in patients during a recently completed first-stage study. The biotech company is gearing up for midstage trials to test the safety and effectiveness of the drug.

Related Summaries